Evening of March 9, Sinopharm Group’s two listed companies Modern Pharmaceutical (600420), Sinopharm agreement also released a major asset restructuring announcement. After completion of the transaction, the modern pharmaceutical and Sinopharm Sinopharm were to become consistent with the Group of medicine and business platform.
According to the announcement, the modern pharmaceutical intended to 29.11 yuan / share non-public offering of a total of 264 million shares, cash and 065 million yuan, the total price of 7.744 billion yuan acquisition-related industrial assets; at the same time, intended to 29.11 yuan / share to Sinopharm, Sinopharm three and other objects of the nine non-public offering of shares to raise matching funds are not more than 1.9 billion yuan.
Modern Pharmaceutical Sinopharm issued shares to buy its 51% stake held in Wuhu Sanyi, Medicines bent 26% stake in Sinopharm issued shares to buy its 25% stake held by bent to Hangzhou Lake Creek; agreed to issue shares to buy its holding Sinopharm some Zhijun pharmaceutical 51% stake, 51% stake in Ping Shan pharmaceutical, Zhijun trade 51% stake in Ping Shan base of operating assets; Sinopharm industry to issue shares to buy their holdings of industrial and limited 100% stake in Sinopharm Weiqi Da 67% stake and 80% stake in Shantou Jinshi, Qinghai, 52.92% stake in the pharmaceutical, Xinjiang pharmaceutical 55% interest; issue of shares and payment of cash to buy a 33% stake it holds a 33% stake in Sinopharm and Weiqi Da pharmaceutical anti-Han Yanlin to a natural person;杨时浩 issued shares to buy other 12 natural persons 20% stake held by Shantou Jinshi.
Medicines consistent set of newly issued shares to subscribe for modern pharmaceutical industry pharmaceutical assets, while the proposed acquisition of shares and cash assets related pharmaceutical business issue.
The number of shares after the transaction is completed, Medicines consistent with modern pharmaceutical assets subscribe new issue is expected to be 8627.12 million shares, accounting for 13.99 percent after the completion of total issued share capital of modern pharmaceuticals. At the same time, intended to 53.80 yuan / share non-public offering to Sinopharm shares to buy 100% stake in National pharmacy, 100% stake in Foshan, Guangdong new drugs 100% stake in Sinopharm Foreign non-public offering later Southern Medical Trade 51% equity, and pay cash to buy 49% stake in Southern Medical trade and other groups to break 11 months of natural persons of minority shareholders, the estimated value of assets to be injected 3.495 billion yuan. In terms of matching funds, to be adopted by way of price to lock towards investment management, peace and information management, Sinopharm non-public offering of shares to raise matching funds $ 700 million to raise matching funds issue price of 53.80 yuan / share.
The completion of the transaction, will build a modern pharmaceutical Sinopharm Group Kayaku plate platform, the main business will complement the cardiovascular drugs, antibiotics, systemic medication, anti-tumor drugs, narcotic and other psychotropic. Sinopharm Holdings is no longer consistent with the pharmaceutical industry-related assets, while the new national information pharmaceutical retail business, main business will change to “+ retail distribution.”